Literature DB >> 22287093

NMR assignments of the FKBP-type PPIase domain of the human aryl-hydrocarbon receptor-interacting protein (AIP).

Miriam Linnert1, Katja Haupt, Yi-Jan Lin, Sandra Kissing, Anne-Katrin Paschke, Gunter Fischer, Matthias Weiwad, Christian Lücke.   

Abstract

The aryl-hydrocarbon receptor-interacting protein (AIP) interacts with several protein binding partners and has been associated with pituitary tumor development. Here, we report nearly complete (1)H, (13)C and (15)N chemical shift assignments for the N-terminal AIP(2-166) segment, which has been predicted to represent a FKBP-type PPIase domain. Sequence alignment with the prototypic FKBP12, however, reveals disagreements between the AIP chemical shift index consensus and the corresponding FKBP12 secondary structure elements.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22287093     DOI： 10.1007/s12104-012-9359-0

Source DB:  PubMed          Journal:  Biomol NMR Assign        ISSN： 1874-270X            Impact factor:   0.746


  9 in total

1.  A novel C-terminal nonsense mutation, Q315X, of the aryl hydrocarbon receptor-interacting protein gene in a Japanese familial isolated pituitary adenoma family.

Authors:  Takeo Iwata; Shozo Yamada; Junko Ito; Naoko Inoshita; Noriko Mizusawa; Shinji Ono; Katsuhiko Yoshimoto
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

2.  Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?

Authors:  Z Karaca; S Taheri; F Tanriverdi; K Unluhizarci; F Kelestimur
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  NMR resonance assignments of the FKBP domain of human aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) in complex with a farnesyl ligand.

Authors:  Liping Yu; Ravi P Yadav; Nikolai O Artemyev
Journal:  Biomol NMR Assign       Date:  2017-02-24       Impact factor: 0.746

4.  Should aip gene screening be recommended in family members of FIPA patients with R16H variant?

Authors:  Maria Chiara Zatelli; Maria Luisa Torre; Rachele Rossi; Marta Ragonese; Francesco Trimarchi; Ettore degli Uberti; Salvatore Cannavò
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

5.  A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma.

Authors:  Roberto Salvatori; Adrian F Daly; Alfredo Quinones-Hinojosa; Albert Thiry; Albert Beckers
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-08-01

6.  Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland.

Authors:  Laura C Hernández-Ramírez; Rhodri M L Morgan; Sayka Barry; Fulvio D'Acquisto; Chrisostomos Prodromou; Márta Korbonits
Journal:  Oncotarget       Date:  2018-01-11

7.  Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion.

Authors:  Marko Stojanovic; Zida Wu; Craig E Stiles; Dragana Miljic; Ivan Soldatovic; Sandra Pekic; Mirjana Doknic; Milan Petakov; Vera Popovic; Christian Strasburger; Márta Korbonits
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

8.  Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal α-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition.

Authors:  Rhodri M L Morgan; Laura C Hernández-Ramírez; Giampaolo Trivellin; Lihong Zhou; S Mark Roe; Márta Korbonits; Chrisostomos Prodromou
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

9.  In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism.

Authors:  Roberto Salvatori; Serban Radian; Yoan Diekmann; Donato Iacovazzo; Alessia David; Plamena Gabrovska; Giorgia Grassi; Anna-Marie Bussell; Karen Stals; Astrid Weber; Richard Quinton; Elizabeth C Crowne; Valentina Corazzini; Lou Metherell; Tara Kearney; Daniel Du Plessis; Ajay Kumar Sinha; Atik Baborie; Anne-Lise Lecoq; Philippe Chanson; Olaf Ansorge; Sian Ellard; Peter J Trainer; David Balding; Mark G Thomas; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2017-06-20       Impact factor: 6.558
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.